ClinicalTrials.gg
CompletedNCT06127212Updated Nov 13, 2023

Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets

An interventional study of Dapagliflozin 10 mg film-coated tablet and Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia in Healthy, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Dexa Medica Group · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Mar 2023, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study was an open-label, randomized, single-dose, two-period, two-sequence, two-day crossover study, conducted to find out whether the dapagliflozin 10 mg film-coated tablet produced by PT Dexa Medica (test drug) was bioequivalent to the reference drug (Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia), under fasting condition with a five days wash-out period, involving 24 healthy adult male and female subjects.

Read the detailed description

The study was an open-label, randomized, single-dose, two-period, two-sequence, two-day crossover study, conducted to find out whether the dapagliflozin 10 mg film-coated tablet produced by PT Dexa Medica (test drug) was bioequivalent to the reference drug (Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia), under fasting condition with a five days wash-out period, involving 24 healthy adult male and female subjects. The participating subjects had an overnight fast and in the next morning were given orally either one film-coated tablet of the test drug or one film-coated tablet of the reference drug with a total 240 mL of a 20% glucose solution in water. Following drug administration, 60 mL of 20% glucose solution was administered at every 15 minutes for up to 4 hours after dosing as maintenance to prevent hypoglycemic symptoms. Blood samples were drawn before taking the drug (control) and at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50,1.75, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 24.00, 36.00 and 48.00 hours after drug administration. The blood samples were analyzed to investigate the pharmacokinetics parameters of the single dose administration of dapagliflozin. The plasma concentrations of dapagliflozin were determined by using a validated ultra-performance liquid chromatography with tandem mass spectroscopy detection (UPLC-MS/MS).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to participate, communicate well with the investigators and willing to provide written to participate in the study.
  2. Healthy male and female subjects with absence of significant disease or abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening and could be considered healthy based on the evaluation.
  3. Aged 18 - 55 years inclusive.
  4. Preferably non-smokers or smoke less than 10 cigarettes per day.
  5. within 18 to 25 kg/m2
  6. Vital signs (after 10 minutes rest) must be within the following ranges:

    • Systolic blood pressure: 100 - 129 mmHg
    • Diastolic blood pressure: 60 - 84 mmHg
    • Pulse rate: 60 - 90 bpm.
  7. Willing to practice abstention or during the study

Exclusion criteria

Exclusion Criteria:

  1. History of allergy or or to dapagliflozin or allied drugs.
  2. Pregnant or lactating female (urinary pregnancy test was applied to female subjects at screening and before taking the study drug).
  3. Any major illness in the past 90 days or ongoing chronic medical illness.
  4. Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test (, ALT, alkaline phosphatase, total , direct bilirubin ≥ 1.5 ), renal function test (serum creatinine concentration > 1.4 mg/dL and ureum ≥ 1.5 ULN), etc.
  5. Positive surface antigen (HBsAg), anti-, or anti-.
  6. Positive result for COVID-19 rapid antigen test.
  7. Clinically significant hematology abnormalities.
  8. Clinically significant (ECG) abnormalities.
  9. Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery.
  10. Past history of anaphylaxis or angioedema.
  11. History of drug or alcohol abuse within 12 months prior to screening for this study.
  12. Participation in any clinical trial within the past 90 days calculated from the last visit until this study's first dosing day.
  13. History of any bleeding or coagulative disorders.
  14. Presence of difficulty in accessibility of veins in left or right arm.
  15. A donation or significant blood loss within 90 days before this study's first dosing day.
  16. Intake of any prescription (especially dapagliflozin and empagliflozin), non-prescription drug (including hormonal ), food supplements or herbal medicines within 21 days of this study's first dosing day.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Test Dapagliflozin Dexa Medica

    Dapagliflozon 10 mg Film-Coated tablet, produced by PT Dexa Medica, Indonesia.

    Drug: Dapagliflozin 10 mg film-coated tablet

  • Active comparator
    Reference Forxiga AstraZeneca

    Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia.

    Drug: Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-t)

    Area under the plasma concentration-time curve to the last observer quantifiable concentration at time t

    Time frame: 48 hours

  2. Cmax

    Maximum plasma concentration

    Time frame: 48 hours

Secondary outcomes

  1. AUC(0-inf)

    Area under the plasma concentration-time curve extrapolated to infinitive time

    Time frame: 48 hours

  2. T1/2

    Plasma half-life

    Time frame: 48 hours

  3. Tmax

    Time taken to reach maximum observed plasma concentration

    Time frame: 48 hours

07

Study locations

1 site
  • PT Equilab International
    Jakarta, 12430, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Mar 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Mar 8, 2023
Primary completionActual
Mar 15, 2023
CompletionActual
May 6, 2023
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06127212
Lead sponsor
Dexa Medica Group
Collaborators
PT Equilab International
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Mar 8, 2023
Primary completion
Mar 15, 2023
Completion
May 6, 2023
Last update
Nov 13, 2023

Study contacts

Danang A Yunaidi, MD
principal investigator · Equilab International

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion